A Cartalax Certificate of Analysis (COA) is an official analytical document verifying the identity, chemical purity, and biological cleanliness of a specific manufacturing lot. Designed for quality assurance officers and laboratory researchers, this documentation confirms that the synthetic peptide meets rigorous standards before deployment in cell culture or preclinical models.
A Cartalax Certificate of Analysis (COA) is an official analytical document verifying the identity, chemical purity, and biological cleanliness of a specific manufacturing lot. Designed for quality assurance officers and laboratory researchers, this documentation confirms that the synthetic peptide meets rigorous standards before deployment in cell culture or preclinical models.
A Cartalax Certificate of Analysis is an independent quality document providing empirical verification of a peptide batch's identity, purity, and safety profile. It includes reverse-phase high-performance liquid chromatography (RP-HPLC) chromatograms, liquid chromatography-mass spectrometry (LC-MS) mass confirmation, quantitative endotoxin testing, and physical characterization data.
When purchasing high-purity Cartalax for empirical research, reviewing a lot-specific COA ensures that the target tripeptide is free from truncated sequences, residual reagents, or heavy metal contamination. Laboratory environments require total transparency regarding reagent composition to eliminate uncontrolled variables during assay execution and data collection.
Cartalax is a synthetic tripeptide composed of the amino acid sequence L-alanyl-L-glutamyl-L-aspartic acid (Ala-Glu-Asp or AED). Classified within the short peptide bioregulator category, Cartalax has a theoretical molecular formula of C12H19N3O8 and a monoisotopic molecular weight of approximately 333.29 g/mol (with a target protonated mass [M+H]+ of ~334.3 Da or sodium adduct variations depending on salt form).
An authentic COA explicitly references these chemical identifiers alongside the lot number, date of synthesis, net peptide content, and appearance (typically a white to off-white lyophilized powder). In published preclinical research, verifying the precise sequence integrity of short peptide chains is critical, as minor deletions or substitution impurities can substantially alter binding kinetics and downstream cellular signaling.
Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) is the primary analytical method used to quantify the purity of Cartalax. The COA provides a detailed chromatographic trace showing peak retention times against a baseline, calculated using an ultraviolet (UV) detector typically set between 214 nm and 220 nm to capture peptide backbone absorbance.
Purity is expressed as a peak area percentage (Area %). High-grade laboratory reagents supplied by PX1 Research guarantee an RP-HPLC purity of ≥98.0%. The main analyte peak for Cartalax must stand sharply distinct from any minor secondary peaks, which represent synthesis side-products such as deletion sequences, oxidized species, or protecting group residues. A clean chromatographic baseline ensures minimal analytical noise in cell viability, gene expression, or enzyme kinetic assays.
While HPLC measures chemical purity by separating molecular species, Liquid Chromatography-Mass Spectrometry (LC-MS) confirms the exact identity of the primary peak. The COA includes mass spectra generated via electrospray ionization (ESI-MS) to measure the mass-to-charge ratio (m/z) of the sample.
For Cartalax, the primary m/z peak corresponds directly to the expected molecular mass of the Ala-Glu-Asp peptide chain. The presence of expected ion adducts (such as [M+H]+ or [M+Na]+) without spurious mass peaks confirms that the synthesized peptide matches its theoretical primary sequence. Mass spectrometry validation prevents false positives caused by co-eluting impurities that share similar retention times under HPLC conditions.
Bacterial endotoxins (lipopolysaccharides or LPS) pose a major threat to in vitro assays, particularly primary cell cultures and tissue explants sensitive to inflammatory signaling. A thorough Cartalax COA includes quantitative endotoxin data obtained through the Limulus Amebocyte Lysate (LAL) assay or recombinant Factor C (rFC) testing.
PX1 Research mandates strict endotoxin thresholds (typically <0.1 EU/mg or <0.05 EU/vial) across all research peptide lots. Quantifying endotoxins on the batch documentation ensures that observed biological responses—such as changes in cartilage matrix synthesis or cellular proliferation—are attributable solely to the peptide target rather than pyrogenic contamination. Bulk requisitions for academic institutions and biotech labs can review comprehensive quality documentation via our wholesale peptide program.
Cartalax has been investigated extensively in preclinical models evaluating connective tissue dynamics, chondrocyte homeostasis, and extracellular matrix (ECM) regulation. In vitro data indicate that short peptide bioregulators like Ala-Glu-Asp penetrate cell membranes and interact directly with chromatin structures, influencing gene expression profiles associated with structural protein synthesis.
In vitro cell culture assays involving mammalian chondrocytes demonstrate that exposure to Cartalax may support the transcription of Type II collagen and aggrecan while regulating pro-inflammatory cytokine expression under stress conditions. For detailed mechanistic models, pathways, and transcriptomic analyses, review our comprehensive guide on Cartalax mechanism of action.
When designing comparative connective tissue or peptide bioregulator studies, researchers frequently evaluate Cartalax alongside other short signaling peptides and tissue-repair compounds. Selecting the appropriate control or complementary compound depends on the specific biochemical target and analytical model.
While Cartalax focuses primarily on chondrocyte regulation and cartilage matrix homeostasis, researchers studying systemic cellular aging or pineal gene regulation often utilize Epitalon. Conversely, investigations centered on rapid soft tissue angiogenesis, tendon-to-bone healing, and gastric mucosal repair frequently incorporate BPC-157. Within the broader family of short peptide bioregulators, comparing Cartalax against immune-modulating short peptides detailed in our Khavinson peptides overview provides valuable insights into tissue-specific transcription activation profiles.
To preserve the structural integrity verified on the Certificate of Analysis, proper handling protocols must be maintained upon delivery. Lyophilized Cartalax should be stored at -20°C or -80°C in a desiccated container to prevent moisture absorption and peptide degradation.
Reconstitution should be conducted in a laminar flow hood using sterile, nuclease-free water or phosphate-buffered saline (PBS, pH 7.4). Due to its hydrophilic amino acid composition (glutamic acid and aspartic acid residues), Cartalax dissolves readily in aqueous media without requiring harsh organic solvents. Once reconstituted, aliquots should be frozen immediately to avoid repeated freeze-thaw cycles. Explore our full catalog of research-grade reagents in the all peptides directory.
Not all peptide documentation is created equal. A self-issued manufacturer specification sheet lacks the objective authority of a third-party Certificate of Analysis. PX1 Research submits every production lot of Cartalax to independent, ISO 17025-accredited analytical laboratories located within the United States.
Independent verification ensures unbiased evaluation of purity, identity, counterion content (such as residual trifluoroacetate or acetate salts), and endotoxin limits. USA-manufactured reagents backed by transparent, lot-specific COAs eliminate standard analytical risks, ensuring your laboratory's published findings remain reproducible, robust, and compliant with peer-reviewed scientific standards.
What purity level is guaranteed on a Cartalax Certificate of Analysis from PX1 Research?
Every lot of Cartalax supplied by PX1 Research guarantees a minimum purity threshold of ≥98.0% as determined by RP-HPLC testing.
How do I match my vial of Cartalax to its specific COA?
Each vial features a unique batch/lot number printed on the label. This number directly matches the lot identifier displayed at the top of the corresponding Certificate of Analysis.
Why is LC-MS analysis essential alongside HPLC for Cartalax quality verification?
RP-HPLC confirms the relative purity and quantity of the primary peak, while LC-MS verifies the exact molecular mass (m/z) of the Ala-Glu-Asp structure to rule out sequence errors or co-eluting impurities.
What endotoxin limits are verified on the Cartalax COA?
PX1 Research enforces strict endotoxin limits of <0.1 EU/mg using standardized LAL assay procedures, ensuring safety for cell culture and in vitro experiments.
Does the COA include information about residual counterions?
Yes, detailed lot reports account for counterion identity (such as acetate or TFA salts) and moisture content to provide accurate net peptide content calculations.
Can Cartalax be reconstituted directly in cell culture media?
For standard laboratory procedures, it is recommended to reconstitute lyophilized Cartalax in sterile water or sterile PBS (pH 7.4) first, then dilute into working cell culture media to ensure precise final concentration control.
Where are PX1 Research Cartalax lots manufactured and tested?
All PX1 Research peptides are manufactured in GMP-compliant facilities within the USA and tested by independent, ISO 17025-accredited analytical laboratories.
Is Cartalax approved for human consumption or therapeutic administration?
No. Cartalax is strictly supplied as a research-grade chemical compound for in vitro, cell culture, and laboratory research use only. It is not intended for clinical, human, or veterinary application.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.